Hexahydro-allomaltol | 823-59-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: Hexahydro-allomaltol
• 英文别名: 6-methyl-tetrahydro-pyran-3,4-diol；Pyran-3,4-diol, tetrahydro-6-methyl-；6-methyloxane-3,4-diol
• CAS: 823-59-6
• 化学式: C₆H₁₂O₃
• 分子量: 132.159
• InChiKey: BIWRLNLHQRIBOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Oligosaccharides, preparation method and use thereof, and pharmaceutical compositions containing same
  申请人：Viskov Christian

  公开号：US20070142323A1

  公开（公告）日：2007-06-21

  The invention relates to oligosaccharides, the preparation method and use thereof, and pharmaceutical compositions containing same. More specifically, the invention relates to oligosaccharides which can be used for the treatment of cancer and, in particular, to prevent and inhibit the formation of metastases. The inventive oligosaccharides can be used, for example, during early breast, lung, prostate, colon or pancreatic cancer. The oligosaccharides can be administered subcutaneously, orally or intravenously. Moreover, said oligosaccharides can be used alone or together with other anticancer agents, e.g. cytotoxics such as docetaxel or paclitaxel.
• Therapeutic Heparins and Their Binding to Interleukins 4 and 5 and Pecam-1
  申请人：Coombe Deirdre Roma

  公开号：US20080146522A1

  公开（公告）日：2008-06-19

  The present invention relates generally to chemical agents useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory including allergic diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites. More particularly, the chemical agents contemplated by the present invention are selected from glycosaminoglycan (GAG) molecules derived from a larger GAG, GAG-like molecules which resemble GAGs in some of their characteristics but may be derived from a larger non-GAG polysaccharide and molecules having a GAG-like composite structure as well as agents which bind to the same sites as GAGs, GAG-like molecules or GAG-like composite molecules. The present invention also provides assays to identify GAG and GAG-like therapeutic agents including GAG-like composite structures as well as analogs, homologs and orthologs thereof.